This study aims to demonstrate that DC therapy can suppress inflammation, as indicated by changes in inflammatory biomarkers (IL6, IL-10, and TNF-α), thereby reducing albuminuria in DKD patients. Here, IL10 is linked to diabetic kidney disease.